Key Takeaways:
Pliant Therapeutics presented highly positive updated data from the Phase 1 trial of its drug candidate, PLN-101095, showing an 89 percent average maximum tumor reduction in patients with solid tumors that are refractory to immune checkpoint inhibitors (ICI).
The data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, also showed that confirmed responses deepened and the median time on treatment for patients increased to 19 months, a significant duration for this advanced patient population.
The trial focused on patients with ICI-refractory solid tumors, which are notoriously difficult to treat and represent a high unmet medical need. The 89 percent average reduction in tumor size from baseline is a strong efficacy signal, particularly for a Phase 1 study, which primarily assesses safety.
This strong clinical data de-risks a key asset in Pliant's development pipeline and significantly increases the probability of the drug's eventual success and regulatory approval. The results are likely to attract substantial investor interest and could lead to a surge in the company's stock price. Investors will now look toward the company's next steps for the PLN-101095 development program, including plans for a larger, pivotal trial.
This article is for informational purposes only and does not constitute investment advice.
